Imatinib is not a potent anti-SARS-CoV-2 drug

被引：29

作者：

Zhao, Helong ^{[1
]}

Mendenhall, Michelle ^{[2
]}

Deininger, Michael W. ^{[1
,3
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[2] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA

[3] Univ Utah, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

来源：

LEUKEMIA | 2020年 / 34卷 / 11期

关键词：

RESPIRATORY SYNDROME CORONAVIRUS;

D O I：

10.1038/s41375-020-01045-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3085 / 3087

页数：3

共 15 条

[1] Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
Breccia, Massimo
Abruzzese, Elisabetta
Bocchia, Monica
Bonifacio, Massimiliano
Castagnetti, Fausto
Fava, Carmen
Galimberti, Sara
Gozzini, Antonella
Gugliotta, Gabriele
Iurlo, Alessandra
Latagliata, Roberto
Luciano, Luigiana
Pregno, Patrizia
Rege-Cambrin, Giovanna
Rosti, Gianantonio
Stagno, Fabio
Tiribelli, Mario
Foa, Robin
Saglio, Giuseppe
[J]. LEUKEMIA, 2020, 34 (08) : 2260 - 2261
[2] Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion
Coleman, Christopher M.
Sisk, Jeanne M.
Mingo, Rebecca M.
Nelson, Elizabeth A.
White, Judith M.
Frieman, Matthew B.
[J]. JOURNAL OF VIROLOGY, 2016, 90 (19) : 8924 - 8933
[3] Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Dyall, Julie
Coleman, Christopher M.
Hart, Brit J.
Venkataraman, Thiagarajan
Holbrook, Michael R.
Kindrachuk, Jason
Johnson, Reed F.
Olinger, Gene G., Jr.
Jahrling, Peter B.
Laidlaw, Monique
Johansen, Lisa M.
Lear-Rooney, Calli M.
Glass, Pamela J.
Hensley, Lisa E.
Frieman, Matthew B.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4885 - 4893
[4] Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study
Ector, Genevieve I. C. G.
Huijskens, Elisabeth G. W.
Blijlevens, Nicole M. A.
Westerweel, Peter E.
[J]. LEUKEMIA, 2020, 34 (09) : 2533 - 2535
[5] Targeting non-malignant disorders with tyrosine kinase inhibitors
Grimminger, Friedrich
Schermuly, Ralph T.
Ghofrani, Hossein A.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (12) : 956 - 970
[6] Hoffmann Markus, 2020, bioRxiv, DOI 10.1101/2020.08.05.237651
[7] The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
Janes, Jeff
Young, Megan E.
Chen, Emily
Rogers, Nicole H.
Burgstaller-Muehlbacher, Sebastian
Hughes, Laura D.
Love, Melissa S.
Hull, Mitchell V.
Kuhen, Kelli L.
Woods, Ashley K.
Joseph, Sean B.
Petrassi, H. Michael
McNamara, Case W.
Tremblay, Matthew S.
Su, Andrew I.
Schultz, Peter G.
Chatterjee, Arnab K.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (42) : 10750 - 10755
[8] COVID-19 in persons with chronic myeloid leukaemia
Li, Weiming
Wang, Danyu
Guo, Jingming
Yuan, Guolin
Yang, Zhuangzhi
Gale, Robert Peter
You, Yong
Chen, Zhichao
Chen, Shiming
Wan, Chucheng
Zhu, Xiaojian
Chang, Wei
Sheng, Lingshuang
Cheng, Hui
Zhang, Youshan
Meng, Li
Jiang, Qian
Li, Qing
Qin, Jun
[J]. LEUKEMIA, 2020, 34 (07) : 1799 - 1804
[9] Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Lu, Roujian
Zhao, Xiang
Li, Juan
Niu, Peihua
Yang, Bo
Wu, Honglong
Wang, Wenling
Song, Hao
Huang, Baoying
Zhu, Na
Bi, Yuhai
Ma, Xuejun
Zhan, Faxian
Wang, Liang
Hu, Tao
Zhou, Hong
Hu, Zhenhong
Zhou, Weimin
Zhao, Li
Chen, Jing
Meng, Yao
Wang, Ji
Lin, Yang
Yuan, Jianying
Xie, Zhihao
Ma, Jinmin
Liu, William J.
Wang, Dayan
Xu, Wenbo
Holmes, Edward C.
Gao, George F.
Wu, Guizhen
Chen, Weijun
Shi, Weifeng
Tan, Wenjie
[J]. LANCET, 2020, 395 (10224) : 565 - 574
[10] Imatinib: the narrow line between immune tolerance and activation
Mohty, M
Blaise, D
Olive, D
Gaugler, B
[J]. TRENDS IN MOLECULAR MEDICINE, 2005, 11 (09) : 397 - 402

← 1 2 →